Navigation Links
Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
Date:1/29/2008

LOCATION: http://content.onstreammedia.com/content/multivu/18240/31602.mp3

RICHMOND, VA, January 29 /PRNewswire/ -- The American Magazine has just released a Podcast interview with Insmed Therapeutic Proteins President Steve Glover on how a generic, or follow-on biologics, industry is good for patients and can stem soaring healthcare costs as new therapies increasingly come from biotechnology. The American Magazine is the American Enterprise Institute's magazine of business and economics.

In the podcast, Mr. Glover discusses the need for Congress to establish a clear pathway for the approval, regulation and production of follow-on biologics, enhancing access to biologics therapies for millions of Americans, as the 1984 Hatch-Waxman Act did for pharmaceuticals.

Follow-on biologics are versions of approved biologics that are developed after the original product has been created with the intention of marketing them after the patent on the innovator product has expired, thus bringing competition to monopolistic markets.

Biologics comprise one of the fastest growing and most expensive categories of drugs. It is estimated that 50% of approved pharmaceuticals in 2010 will be biotechnology products, with sales estimated to reach $90 billion.

According to published reports, an estimated $10 billion worth of biologic drugs are expected to come off patent by 2010 (with an additional $10 billion by 2015) but currently are immune from competition. Follow-on biologics would provide safe and effective therapies at a reduced cost following the expiration of the original product's patent.
When: The Podcast is available for immediate download.

Where: http://content.onstreammedia.com/content/multivu/18240/31602.mp3

How: Go to the URL above, to download the audio file.

About Insmed Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Global Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Minimum Requirements: a computer, an Internet connection, (broadband required), a portable MP3/Video player or MP3/Video-player application on your computer, podcasting software and QuickTime 7. If you experience problems downloading the podcast, send an email to webcast@multivu.com.


'/>"/>
SOURCE The American Magazine
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. KGI Names Kerry Howell Vice President for Advancement
5. Vical Names Andrew de Guttadauro Vice President, Corporate Development
6. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
9. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
10. CryoLife Names Philip Theodore as Vice President, General Counsel
11. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... DIEGO , June 27, 2016  Sequenom, Inc. ... committed to enabling healthier lives through the development of ... Court of the United States ... courts that the claims of Sequenom,s U.S. Patent No. ... patent eligibility criteria established by the Supreme Court,s Mayo ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... Chapel Hill, N.C. (PRWEB) , ... June 27, ... ... of U.S. commercial operations for Amgen, will join the faculty of the ... will serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
Breaking Biology Technology:
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):